Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock
Michael S. Poirier, insider at Qualigen Therapeutics
Michael S. Poirier Insider Alerts

Get notified the next time Michael S. Poirier buys or sells Qualigen Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Michael S. Poirier Insider Information

Michael S. Poirier founded Qualigen in 1996 and is its Chairman, President and Chief Executive Officer. Prior to founding Qualigen, Mr. Poirier was Vice President of Marketing for Ashirus Technologies, Inc., a Minneapolis-based manufacturer of innovative high-precision dispensing pumps and related equipment for the medical industry. From 1993 to 1995, Mr. Poirier was Director of US Area Operations for EnSys, Inc., located in Research Triangle, North Carolina. EnSys developed and manufactured field-portable immunoassay test kits for the environmental remediation industry. From 1991 to 1993, Mr. Poirier was employed by Sanofi Pasteur in Chaska, Minnesota, as a Marketing Manager responsible for launching the ACCESS® Immunoassay System. This novel diagnostic system was later acquired by Beckman-Coulter and is now one of the leading immunoassay test systems worldwide. From 1985 to 1991, Mr. Poirier was employed by Abbott Diagnostics, a division of Abbott Laboratories, Inc. in various marketing and sales positions, including Worldwide Immunoassay Product Manager for the IMx® and AxSym® immunoassay diagnostic systems. Both IMx and later, AxSym, became the leaders in their respective markets. Prior to working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zürich, Switzerland, School of Law.

What is Michael S. Poirier's net worth?

The estimated net worth of Michael S. Poirier is at least $267,339.16 as of April 20th, 2021. Mr. Poirier owns 169,202 shares of Qualigen Therapeutics stock worth more than $267,339 as of November 30th. This net worth evaluation does not reflect any other investments that Mr. Poirier may own. Learn More.

What is Michael S. Poirier's salary?

As the CEO of Qualigen Therapeutics, Inc., Mr. Poirier earned a total compensation package of $4,679,131.00 in 2020. Mr. Poirier earned a salary of $363,796.00, a bonus of $251,000.00, options awards of $4,063,412.00, and other compensation of $923.00.

How do I contact Michael S. Poirier?

The corporate mailing address for Mr. Poirier and other Qualigen Therapeutics executives is 2042 Corte Del Nogal, Carlsbad CA, 92011. Qualigen Therapeutics can also be reached via phone at (310) 203-1000 and via email at [email protected]

Has Michael S. Poirier been buying or selling shares of Qualigen Therapeutics?

Michael S. Poirier has not been actively trading shares of Qualigen Therapeutics during the past quarter. Most recently, on Tuesday, April 20th, Michael S. Poirier bought 11,005 shares of Qualigen Therapeutics stock. The stock was acquired at an average cost of $1.80 per share, with a total value of $19,809.00. Following the completion of the transaction, the chief executive officer now directly owns 169,202 shares of the company's stock, valued at $304,563.60.

Who are Qualigen Therapeutics' active insiders?

Qualigen Therapeutics' insider roster includes Amy Broidrick (EVP), Kurt Kruger (Director), and Michael Poirier (CEO).

Are insiders buying or selling shares of Qualigen Therapeutics?

During the last year, Qualigen Therapeutics insiders bought shares 5 times. They purchased a total of 30,205 shares worth more than $55,566.00. The most recent insider tranaction occured on August, 19th when Director Kurt H. Kruger bought 8,000 shares worth more than $9,840.00. Insiders at Qualigen Therapeutics own 4.7 % of the company.

Information on this page was last updated on 8/19/2021.

Michael S. Poirier Insider Trading History at Qualigen Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2021Buy11,005$1.80$19,809.00169,202View SEC Filing Icon  
See Full Table

Michael S. Poirier Buying and Selling Activity at Qualigen Therapeutics

This chart shows Michael S Poirier's buying and selling at Qualigen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Qualigen Therapeutics Company Overview

Qualigen Therapeutics logo
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.
Read More

Today's Range

Now: $1.58
Low: $1.55
High: $2.97

50 Day Range

MA: $1.31
Low: $0.94
High: $2.56

2 Week Range

Now: $1.58
Low: $0.93
High: $4.66

Volume

81,985,284 shs

Average Volume

2,472,137 shs

Market Capitalization

$46.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock